retatrutide phase 2 trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Mazdutide vs retatrutide: dual agonist

Quality verification beyond vendor claims Researchers can implement additional verification steps beyond accepting vendor documentation

Lipid panels offer additional metabolic insight since triglyceride levels correlate with insulin resistance

Risk ratios (RR) for MACE estimates according to direct (DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors against placebo) and indirect (DPP-4 inhibitors vs GLP-1RA or SGLT-2 inhibitors, and GLP-1RA vs SGLT-2 inhibitors) comparisons

It also can't be used with MAO inhibitors

A combination of resistance training at least two to three times per week and protein intake of 1.2 to 1.6 g/kg per day has been shown to preserve and even increase lean mass during caloric restriction

This necessitates careful monitoring and likely medication adjustment